Publicaciones en colaboración con investigadores/as de Consorci Sanitari de Terrassa (35)

2024

  1. Human Leukocyte Antigen Signatures as Pathophysiological Discriminants of Microscopic Colitis Subtypes

    Journal of Crohn's and Colitis, Vol. 18, Núm. 3, pp. 349-359

  2. Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn's Disease: A National, Multicentre Study Based on ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 18, Núm. 4, pp. 578-588

  3. Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 10, pp. 1325-1338

  4. Prevalence of potentially inappropriate medications and prescription dynamics in elderly hospitalized patients in Spain

    BMC Geriatrics, Vol. 24, Núm. 1

  5. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290

  6. Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA

    Pharmaceutics, Vol. 16, Núm. 5

2023

  1. Clinical Presentation, Management, and Evolution of Lymphomas in Patients with Inflammatory Bowel Disease: An ENEIDA Registry Study

    Cancers, Vol. 15, Núm. 3

  2. Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU

    American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046

  3. Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety

    American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247

  4. Setting priorities for an agenda within the Spanish pediatric emergency medicine research network

    European Journal of Pediatrics, Vol. 182, Núm. 8, pp. 3549-3558

2022

  1. Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg)

    Journal of Clinical Medicine, Vol. 11, Núm. 6

  2. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  3. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 2

  4. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24

  5. Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 16, Núm. 6, pp. 946-953

  6. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2021

  1. Efficacy of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: A 3-month follow-up analysis

    BMJ Supportive and Palliative Care, Vol. 11, Núm. 1, pp. 25-31

  2. Electronic health records and patient registries in medical oncology departments in Spain

    Clinical and Translational Oncology, Vol. 23, Núm. 10, pp. 2099-2108

  3. Household Severe Acute Respiratory Syndrome Coronavirus 2 Transmission and Children: A Network Prospective Study

    Clinical Infectious Diseases, Vol. 73, Núm. 6, pp. E1261-E1269

  4. Preoperative nasopharyngeal swab testing and postoperative pulmonary complications in patients undergoing elective surgery during the SARS-CoV-2 pandemic

    British Journal of Surgery, Vol. 108, Núm. 1, pp. 88-96